Citadel Advisors
CMPX icon

Citadel Advisors’s Compass Therapeutics CMPX Stock Holding History

Citadel Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Sell
65,500
-30,000
-31% -$88.6K ﹤0.01% 12389
2026
Q1 		$505K Buy
+95,500
New +$551K ﹤0.01% 9279
2025
Q3 		– Sell
-12,400
Closed -$32.2K – 12901
2025
Q2 		$32.2K Sell
12,400
-157,200
-93% -$324K ﹤0.01% 11956
2025
Q1 		$322K Buy
+169,600
New +$451K ﹤0.01% 9421

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's CMPX Position: Q2 2026 in Review

Citadel Advisors increased its Compass Therapeutics (CMPX) stake by 395% in Q2 2026, buying an estimated $8.41M and bringing the position to 3,570,674 shares worth $7.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3965.

Citadel Advisors first reported a position in CMPX in Q4 2021 and has held it in 11 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Citadel Advisors held 3,570,674 shares of Compass Therapeutics worth $7.82M as of Q2 2026.
  • Citadel Advisors bought 2,849,264 Compass Therapeutics shares in Q2 2026, an estimated $8.41M.
  • Compass Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3965 holding.
  • Citadel Advisors first reported a position in Compass Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.